17.09.2020
Abingdon Health
Abingdon Health announces £1M funding for the development of a quantitative rapid test Smartphone Reader
Innovate UK has released £1M to fund a further next generation development of Abingdon Health’s lateral-flow rapid test readout technology; AppDx®. The project will see the enhancement of AppDx® at an accelerated pace to achieve a fully quantitative smartphone-based solution for the lateral flow assay (LFA) market.
AppDx® is cutting-edge software that transforms a Smartphone camera into a self-sufficient, standalone lateral-flow reader. By utilising connectivity within Smartphones, AppDx® then enables data captured from rapid tests to be securely shared via a data cloud to connected stakeholders.
AppDx® algorithms work under a “bring-your-own-device” model and the software considers test specific and end-user variables as well as vital configuration criteria for different phone models.
Click on the link to read the full story.
Exhibitor Data Sheet
AppDx® is cutting-edge software that transforms a Smartphone camera into a self-sufficient, standalone lateral-flow reader. By utilising connectivity within Smartphones, AppDx® then enables data captured from rapid tests to be securely shared via a data cloud to connected stakeholders.
AppDx® algorithms work under a “bring-your-own-device” model and the software considers test specific and end-user variables as well as vital configuration criteria for different phone models.
Click on the link to read the full story.
Exhibitor Data Sheet